You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康德萊醫械(01501.HK)子公司上海翰凌股本將增至5815萬元
格隆匯 06-07 22:39

格隆匯6月7日丨康德萊醫械(01501.HK)發佈公吿,2021年6月7日,公司與上海翰凌、樑棟科博士(公司董事會主席、執行董事及總經理)、股份激勵平台及上海翰凌餘下現有股東訂立增資協議,據此,上海翰凌的股本將由人民幣5000萬元增至人民幣5815萬元,梁博士及股份激勵平台分別以代價人民幣581.5萬元及人民幣233.5萬元認購上海翰凌10.00%及約4.02%擴大後的股權。待增資及股權認購事項完成後,公司於上海翰凌的股權將由69.00%降至約59.33%。上海翰凌仍將為公司的非全資子公司。

上海翰凌致力於心臟瓣膜相關生產技術的研究及開發,其管線產品包括經導管主動脈瓣膜系統、可擴張血管鞘系統及自定位瓣膜擴張球囊導管。截至2020年12月31日止年度,上海翰凌的經審核總資產及淨虧損分別約為人民幣2267.3萬元及1468.3萬元。於該公吿日期,上海翰凌並無可識別收入流。上海翰凌的增資及股權認購事項將提供額外的資金,以支持正在進行及潛在的研發項目,包括研發成本、材料、設備、人力資源、臨牀試驗、檢驗、註冊及取樣等成本及開支。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account